Table 1.
Patient Baseline Characteristics
| Characteristic | Patients (n = 102) (%) |
|---|---|
| Median age (range), years | 52 (22–78) |
| Histology | |
| Squamous | 75 (73.5) |
| Adenocarcinoma | 27 (26.5) |
| Disease status | |
| Recurrent | 48 (47.1) |
| Metastatic | 54 (52.9) |
| Location of metastasis | |
| Lymph node only | 15 (14.7) |
| Lung only | 12 (11.8) |
| Lung and lymph node | 9 (8.8) |
| Bone | 7 (6.9) |
| Liver | 4 (3.9) |
| Multi-site | 17 (16.7) |
| Time to recurrence | |
| ≤ 6 months | 44 (43.1) |
| > 6 months | 58 (56.9) |
| Previous therapy | |
| Surgery | 47 (46.1) |
| Radiotherapy | 80 (78.4) |
| Chemotherapy | 92 (90.2) |
| Anti-angiogenic therapy | 19 (18.6) |
| Lines of therapy | |
| 1 | 35 (34.3) |
| 2 | 39 (38.2) |
| ≥ 3 | 28 (27.5) |
| Treatment pattern | |
| PD-1 monotherapy | 24 (23.5) |
| PD-1+chemotherapy | 26 (25.5) |
| PD-1+chemotherapy+anti-angiogenic therapy | 52 (51.0) |
Notes: Data are presented as No(%) unless otherwise indicated. Time to recurrence, recurrence occurred after first-line therapy.
Abbreviation: PD-1, programmed death-1.